A Remotely Controlled and Powered Artificial Heart Pump

Mussivand, Tofy; Hendry, Paul; Masters, Roy G.; Holmes, Kevin S.; Hum, Albert; Keon, Wilbert J.

doi:10.1111/j.1525-1594.1996.tb00682.x

Cited by 12 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rechargeable batteries, such as NiCd or NiMH, with 1-AH capacity can run the TAH for 30–45 min. An intrathoracic pulsatile artificial heart pump was then developed by Canadian scientists 51 . This was a remotely controlled and powered artificial heart pump via transcutaneous energy transfer and biotelemetry systems, with no percutaneous connections required.…”

Section: Mechanical Engineeringmentioning

confidence: 99%

“…An intrathoracic pulsatile artificial heart pump was then developed by Canadian scientists. 51 This was a remotely controlled and powered artificial heart pump via transcutaneous energy transfer and biotelemetry systems, with no percutaneous connections required. The electrohydraulic system can be used either as a VAD or with modifications as a TAH.…”

Section: Total Artificial Heart (Tah) Implantationmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come

et al. 2019

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

Chronic heart failure (CHF) is a challenging burden on public health. Therapeutic strategies for CHF have developed rapidly in the past decades from conventional medical therapy, which mainly includes administration of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists, to biomedical engineering methods, which include interventional engineering, such as percutaneous balloon mitral valvotomy, percutaneous coronary intervention, catheter ablation, biventricular pacing or cardiac resynchronization therapy (CRT) and CRT-defibrillator use, and implantable cardioverter defibrillator use; mechanical engineering, such as left ventricular assistant device use, internal artery balloon counterpulsation, cardiac support device use, and total artificial heart implantation; surgical engineering, such as coronary artery bypass graft, valve replacement or repair of rheumatic or congenital heart diseases, and heart transplantation (HT); regenerate engineering, which includes gene therapy, stem cell transplantation, and tissue engineering; and rehabilitating engineering, which includes exercise training, low-salt diet, nursing, psychological interventions, health education, and external counterpulsation/enhanced external counterpulsation in the outpatient department. These biomedical engineering therapies have greatly improved the symptoms of CHF and life expectancy. To date, pharmacotherapy, which is based on evidence-based medicine, large-scale, multi-center, randomized controlled clinical trials, is still a major treatment option for CHF; the current interventional and mechanical device engineering treatment for advanced CHF is not enough owing to its individual status. In place of HT or the use of a total artificial heart, stem cell technology and gene therapy in regenerate engineering for CHF are very promising. However, each therapy has its advantages and disadvantages, and it is currently possible to select better therapeutic strategies for patients with CHF according to cost-efficacy analyses of these therapies. Taken together, we think that a new era of biomedical engineering for CHF has begun.

show abstract

Section: Mechanical Engineeringmentioning

confidence: 99%

Section: Total Artificial Heart (Tah) Implantationmentioning

confidence: 99%

Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come

et al. 2019

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

show abstract

“…The HeartSaver VAD system as shown in Figure 1 is a pulsatile electro-hydraulically actuated VAD described previously (11)(12)(13)(14). It utilizes implanted components (Figure 2), including the VAD unit, internal battery, and implanted energy and information transfer coil, as well as external components (Figure 3), including the remote biotelemetry monitor, external battery, and external energy, and information transfer coil.…”

Section: Device Descriptionmentioning

confidence: 99%

HeartSaver VAD: A Totally Implantable Ventricular Assist Device. Results of In Vivo Studies

Mussivand,

Henry,

Masters

et al. 2000

J Extra Corpor Technol

View full text Add to dashboard Cite

Currently, the most widely utilized ventricular assist devices (VADs) require percutaneous connections and are located either externally (e.g., Thoratec, Abiomed) or intra-abdominally (e.g., Novacor, TCI). These attributes have been implicated in a variety of complications (infection, thromboembolic, gastrointestinal, etc.). To address these concerns, a totally implantable VAD that requires no percutaneous connections and can be implanted in the left hemi-thorax has been developed. The developed device has undergone in vivo evaluation as part of the design and development process. A total of 43 implants in the bovine model, with 5 device versions, have been conducted between July 1992 and February 2000. These studies successfully have demonstrated several important aspects of the developed device, including 1) feasibility of a totally implantable system; 2) capability of the device to support a dysfunctional heart; and 3) ability of the device to provide flows up to 10 L/min in a physiological setting. The studies to date have played a vital role in the design and development process as well as demonstrating the feasibility of a totally implantable intrathoracic VAD. Based on these studies, design optimization was conducted, resulting in the development of the pre-clinical version of the device in preparation for clinical trials.

show abstract

“…El empleo de dispositivos de asistencia circulatoria mecánica como la contrapulsación aórtica, el hemopums, la bomba centrífuga, la bomba Axipum, el dispositivo DeBakey/NASA, la bomba rotatoria a flujo pulsátil desarrollada en China y el corazón artificial eléctrico, 7,8 han evitado fallos de bomba agudos, o, en el mejor de los casos, han servido de puente para el transplante cardiaco.…”

Section: Introductionunclassified

Costo-efectividad de la resincronización biventricular como alternativa de tratamiento de la insuficiencia cardiaca

Guzmán¹,

Molina²,

Mariño³

et al. 2009

Rev. cub. salud pública

View full text Add to dashboard Cite

cardiaca refractaria a tratamiento. La variable de efectividad considerada fue: muerte evitada. Resultados El 76,6 % de los enfermos eran del sexo masculino y el 23,4 % del sexo femenino. La mortalidad fue de 36,6 % en el período de seguimiento. La efectividad del proceder alcanzó el 63,4 %, con 19 muertes evitadas. El costo efectividad incremental fue de 33 805,00 pesos. Conclusiones La introducción en Cuba de la alternativa de tratamiento de la insuficiencia cardiaca, conocida como resincronización biventricular resulta costo-efectiva.

show abstract

A Remotely Controlled and Powered Artificial Heart Pump

Cited by 12 publications

References 9 publications

Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come

Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come

HeartSaver VAD: A Totally Implantable Ventricular Assist Device. Results of In Vivo Studies

Costo-efectividad de la resincronización biventricular como alternativa de tratamiento de la insuficiencia cardiaca

Contact Info

Product

Resources

About